(Q36817031)

16 August 2017

1 reference

title

Fampridine-SR for multiple sclerosis and spinal cord injury (English)

1 reference

16 August 2017

0 references

Keith C Hayes

1

1 reference

16 August 2017

publication date

1 May 2007

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

16 August 2017

published in

1 reference

16 August 2017

volume

7

1 reference

16 August 2017

issue

5

1 reference

16 August 2017

page(s)

453-461

1 reference

Spinal cord injury is accompanied by chronic progressive demyelination.

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.453

New concepts in the immunopathogenesis of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.453

Axonal pathology in multiple sclerosis: relationship to neurologic disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.453

Overcoming conduction failure in demyelinated nerve fibres by prolonging action potentials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.453

Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.453

4-Aminopyridine leads to restoration of conduction in demyelinated rat sciatic nerve.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.453

The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.453

Pharmacokinetic studies of single and multiple oral doses of fampridine-SR (sustained-release 4-aminopyridine) in patients with chronic spinal cord injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.453

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.453

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.453

Epidemiology of traumatic spinal cord injury in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.453

Incidence, prevalence and epidemiology of spinal cord injury: what learns a worldwide literature survey?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.453

Interferon-beta1b for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.453

Apoptosis after traumatic human spinal cord injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.453

Demyelination and remyelination after acute spinal cord compression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.453

Spontaneous long-term remyelination after traumatic spinal cord injury in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.453

Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.453

Effects of 4-aminopyridine on neuromuscular transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.453

Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.453

Pharmacokinetics of an Immediate‐Release Oral Formulation of Fampridine (4‐Aminopyridine) in Normal Subjects and Patients with Spinal Cord Injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.453

Evaluation of 4-aminopyridine and 3,4-diaminopyridine penetrability into cerebrospinal fluid in anesthetized rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.453

Absorption characteristics of sustained-release 4-aminopyridine (fampridine SR) in patients with chronic spinal cord injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.453

Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.453

An unusual case of 4-aminopyridine toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.453

Poisoning with 4-Aminopyridine: Report of Three Cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.453

Opisthotonic posturing with neuromuscular irritability attributable to 4-aminopyridine ingestion by a healthy pediatric patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.453

Atypical presentation of 4-aminopyridine overdose

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.453

The use of 4-aminopyridine (fampridine) in demyelinating disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.453

Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.453

Dose responses of three 4-aminopyridine derivatives on axonal conduction in spinal cord trauma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.453

Development of novel 4-aminopyridine derivatives as potential treatments for neurological injury and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.453

4-aminopyridine restores visual ocular motor function in upbeat nystagmus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.453

Potassium channel blockers inhibit the triggers of attacks in the calcium channel mouse mutant tottering.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.453

Intrathecal administration of 4-aminopyridine in chronic spinal injured patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.453

K(+) channels as therapeutic drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.5.453

21 January 2018

Identifiers

DOI

10.1586/14737175.7.5.453

1 reference

16 August 2017

1 reference